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Longitudinal measures of circulating leptin and ghrelin
concentrations are associated with the growth of young Peruvian
children but are not affected by zinc supplementation13
Joanne E Arsenault, Peter J Havel, Daniel Lo´pez de Roman˜a, Mary E Penny, Marta D Van Loan, and
Kenneth H Brown
ABSTRACT
Background: Leptin, ghrelin, and insulin are hormonal regulators
of energy balance and, therefore, may be related to growth during
infancy. Zinc is essential for growth, and its growth effects may be
mediated through these hormones.
Objective: We examined the effects of supplemental zinc on plasma
leptin, ghrelin, and insulin concentrations among young children at
risk of zinc deficiency and examined the relations between these
hormones and physical growth.
Design: Children (n 142) aged 6–8 mo were randomly assigned
to receive 3 mg Zn/d as a supplement, in a fortified food, or as a
placebo for 6 mo. Relations between hormones and anthropometric
z scores, body composition, and growth rates were examined at
baseline and 3 and 6 mo after the start of the intervention.
Results: No treatment group–related differences were found in
plasma leptin, ghrelin, or glucose concentrations or in anthropomet-
ric z scores at 3 or 6 mo after the start of the zinc intervention. Neither
plasma leptin nor ghrelin concentrations at baseline or 3 mo were
predictive of subsequent changes in growth. However, changes in
weight-for-age z scores over the two 3-mo time intervals were pos-
itively associated with subsequent leptin concentrations and in-
versely associated with subsequent plasma ghrelin concentrations.
Conclusions: Supplemental zinc did not affect the children’s
growth, anthropometric indexes, or plasma hormone concentrations
in this study population. Our results suggest that plasma leptin and
ghrelin concentrations in later infancy are a consequence of previous
weight changes rather than predictors of short-term growth. Am
J Clin Nutr 2007;86:1111–9.
KEY WORDS Zinc, leptin, ghrelin, insulin, growth, infants
INTRODUCTION
Supplemental zinc increases linear growth and weight gain in
zinc-deficient animals (1) and in young, stunted children (2).
Zinc may stimulate dietary intake, possibly through hormonal or
neuroendocrine transmitters that affect appetite and thereby pro-
mote increased growth (3). Hormonal factors may also affect
growth directly.
Leptin is a hormone produced primarily in the adipose tissue
and is positively associated with body fat mass (FM) and recent
energy intake. Circulating leptin signals the brain that body fat
stores and energy intake are adequate, thereby suppressing ap-
petite (4). In contrast, ghrelin, which is secreted into the circu-
lation primarily from the stomach, provides a hunger signal to the
brain. Insulin stimulates leptin production and secretion and is
likely to be involved in suppressing ghrelin secretion after meals
(5). Zinc is necessary for insulin synthesis and secretion (6). One
human trial of induced zinc deficiency conducted in men showed
lower leptin concentrations during zinc deficiency and higher
leptin concentrations after zinc repletion (7).
Leptin and ghrelin may influence growth during infancy. Lep-
tin concentrations are high in cord blood (8), and a positive
relation between plasma leptin concentrations and body weight
or body mass index (BMI) has been reported in infants (8–11). In
contrast, circulating ghrelin is negatively associated with body
weight in infants (10, 12–14).
The primary objective of the present set of analyses was to
determine whether supplemental zinc would affect plasma lep-
tin, ghrelin, and insulin concentrations in children assumed to be
at risk of zinc deficiency. Additionally, we examined longitudi-
nally the relations between these hormones and anthropometric
indicators of physical growth. We hypothesized that 1) children
receiving supplemental zinc would have higher plasma hormone
concentrations at 3 mo, 6 mo, or both after starting supplementation
than would children not receiving additional zinc; and 2) the hor-
mone concentrations would be predictive of subsequent growth.
SUBJECTS AND METHODS
Subjects
The children included in this study were a subset of a larger
cohort enrolled in a randomized, double-blind, community-
based trial designed to examine the effects of additional zinc
intake on children’s growth, morbidity, and energy intake. Chil-
dren were selected, by location of residence, to participate in
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substudies to measure hormones involved in energy balance and
assessment of their body composition. The trial was conducted in
a low-income, periurban community in Trujillo, a coastal city in
northern Peru. Children aged 5–7 mo of age were identified
initially by conducting a census, and they were then invited to
attend a screening examination to measure their weight, length,
and hemoglobin concentration. Children were selected if they
met the following inclusion criteria: length-for-age z score
(LAZ)0.5, weight-for-length z score (WLZ)3, hemo-
globin 8 g/dL, no congenital or chronic conditions affecting
growth, no use of infant formula (providing 1 mg Zn/d, 5
times/wk), no twin enrolled in the study, and an intention to live
in the study community during the next 7 mo. Within 2 d of the
screening exam, a worker visited the home of eligible children
whose families were interested in participating in the interven-
tion study to obtain written informed consent. A total of 163
children were enrolled in the present study. The protocol was
approved by the Institutional Review Boards of the University of
California, Davis, and the Instituto de Investigacio´n Nutricional,
Lima, Peru´.
Zinc treatments
Randomization to treatment group occurred 1 mo after enroll-
ment. During the month before randomization, the caregivers of
21 children decided not to continue in the study, and the remain-
ing 142 children were assigned to 1 of 3 groups: 1) wheat-based
porridge without added zinc and a liquid multivitamin supple-
ment with zinc (ZnSuppl), 2) the same porridge fortified with
added zinc and a liquid multivitamin supplement without zinc
(ZnFort), or 3) porridge without zinc and a liquid multivitamin
supplement without zinc (control) (Figure 1). Details of the zinc
treatments were described previously (15). In brief, the zinc-
fortified porridge was designed to provide an additional 3 mg
Zn/d (as zinc sulfate), assuming an average porridge consump-
tion of 20 g/d dry weight, as was observed in a previous study in
Peru (16). The liquid multivitamin supplement with added zinc
(as zinc sulfate) provided 3 mg Zn/d along with vitamins A, B-6,
C, D, and E; thiamine; riboflavin; pantothenic acid; biotin; and
niacin.
Biochemical analyses
Venous blood was collected at 0, 3, and 6 mo after the initiation
of the zinc intervention. Because of the impracticality of obtain-
ing fasting blood samples from predominately breastfed infants
in a community-based setting, the children were brought to the
study office at0730–0800 and allowed to breastfeed. All food
was then withheld until blood was drawn 90 min after the end of
the feeding. The amount of breast milk consumed during this
feeding was measured by weighing the children before and after
the feeding with an electronic infant balance with 5 g precision
(Baby Scale model 231; Seca, Hamburg, Germany). Children
who were not breastfeeding were fed the typical non-human milk
substitute used in this community (reconstituted evaporated or
powdered cow milk), and the amounts of milk and water were
weighed with an electronic balance with 0.1 g precision (MX200;
MyWeigh, Phoenix, AZ). Venous blood (2 mL) was collected
into EDTA-coated tubes and centrifuged immediately. Plasma
was stored initially at20 °C in the field lab and transferred to
Davis on dry ice for storage at80 °C until analyzed.
Infants 5-8 mo of age
screened for eligibility 
Total  (n=927)
For present study only  (n=455)
Excluded (n=292)
Not eligible   (n=270)
Refused to participate (n=22)
Randomization
Left study 
(n=21)
ZnSuppl
(n=47)
ZnFort
(n=49)
Control
(n=46)
3-mo follow-up
Enrollment
Screening
Left study 
(n=7)
Left study 
(n=8)
Left study 
(n=1)
Infants enrolled 
(n=163)
Infants randomly assigned to
treatment group   (n=142)
Left study 
(n=4)
Left study 
(n=3)
Left study 
(n=1)
Infants screened for main study only
(not in present study)   n=472
(n=40)
(n=36)
(n=41) (n=45)
(n=38) (n=44)6-mo follow-up
FIGURE 1. Flow chart of subjects in the study. ZnSuppl, zinc-supplementation group; ZnFort, zinc-fortification group.
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Plasma leptin and insulin were measured by radioimmunoas-
say (LINCO Research, St Charles, MO) with the use of human
antiserum and 125I-labeled peptides. Samples were measured in
duplicate, and all samples from the same subject were measured
in the same analytic run. The mean CVs of the duplicate leptin
and insulin measures were 8.1% and 9.3%, respectively. The
detection limits of the leptin and insulin assays are 0.5 ng/mL and
2 U/mL, respectively. Plasma glucose was measured by the
glucose oxidase method with a glucose analyzer (Yellow Springs
Instruments, Yellow Springs, OH). The mean CV of duplicate
glucose measures was 0.6%.
Plasma ghrelin was measured by radioimmunoassay (Phoenix
Pharmaceuticals Inc, Belmont, CA) with the use of a rabbit an-
tiserum and [125I]ghrelin as a tracer. The mean CV of the dupli-
cate ghrelin measures was 4.1%. The detection limit of the assay
is 64 pg/mL. Because of financial constraints, plasma ghrelin was
measured in only 75% of the study population. The subjects
omitted from ghrelin analyses were randomly selected from the
zinc-fortification group because of the potential variability in
consumption of the porridge and presumed lower zinc absorption
from wheat-based foods.
Anthropometric measures
Anthropometric measures were obtained at baseline and at 3
and 6 mo. Weight was measured on an infant balance with15
g precision (model 345; Seca). Supine length was measured to
0.01 cm by using a digital infantometer (447 Infantronic Digital
Infantometer; Quickmedical, Snoqualmie, WA). All measure-
ments were performed by the same person. The mean CVs for
duplicate measures of weight and length for each infant were
between 0.02% and 0.04% throughout the study. Maternal
weight and height were measured at the time that baseline mea-
sures of the infants were made. The birth weights of the infants
were obtained from the mothers and was verified with written
records if available. The infants’ midupper arm circumference
was measured to the nearest 0.1 cm with a flexible, nonstretch
tape at baseline and 6 mo. Anthropometric z scores for weight and
length were calculated by using EPIINFO software (version 3)
with Centers for Disease Control and Prevention 2000 reference
data (17). Anthropometric z scores for arm circumference were
calculated by using World Health Organization 1997 reference
data (18).
Body composition
Body composition was assessed at baseline and at 6 mo by
using deuterium oxide dilution. A preweighed 0.8-g dose of
deuterium oxide tracer (2H2O) was administered quantitatively
to the children orally with a syringe. Urine samples were col-
lected in plastic urine collection bags before dosing and 2 h
after the dosing. The first urine sample collected 2 h after dosing
was discarded to avoid collection of a nonequilibrated sample,
and the next urine sample was saved for analysis. The average
length of time from dosing to the third urine sample collected
(used for analysis) was 3.6 0.9 h (range: 2.3–9.1 h). The urine
samples were transferred to screw-top vials and stored at20 °C
until processed. The children were allowed to breastfeed during
the body-composition study, and the amount of breast milk con-
sumed was measured as described above. Consumption of other
fluids, such as water and juice, and occasionally other food was
allowed, and these items were weighed with a portable balance
with0.1 g precision (MX200; MyWeigh).
The urine samples were vacuum distilled to obtain pure water,
and 2H2O concentrations were measured in duplicate by infrared
spectrometry (Miran-IFF; Foxboro Co, Foxboro, MA). Total body
water (TBW) was calculated by using the following formula:
TBW [(2H2O dose/2H2O enrichment)] 900 0.96
 0.944] water intake (L) (1)
Corrections were made for the molecular weight of 2H2O relative
to water (900), the nonaqueous hydrogen exchange (0.96) (19),
the fractionation of the isotope (0.944) (20), and the amount of
water consumed during the equilibration period. Water intake
included the water used to rinse the 2H2O vial, breast milk, and
other food and fluids. Fat-free mass (FFM) was calculated by
dividing TBW by the proportion of water in FFM, obtained from
age- and sex-specific reference data (21).
Sample size and statistical analyses
To detect treatment-related differences in plasma concentra-
tions of leptin, ghrelin, and insulin, having an effect size of 0.7
SD, with the use of 3-factor group-wise comparisons and 2-sided
statistical tests, a sample size of 41 subjects per treatment group
was necessary (P 0.05, power of 80%).
Anthropometric measures and plasma hormone concentra-
tions at baseline were compared between zinc-treatment groups
by ANOVA with the use of SAS for WINDOWS (release 8.02;
SAS Institute, Cary, NC). Plasma hormone concentrations were
log transformed because they were not normally distributed. A
mixed model with repeated measures (PROC MIXED) was used
to compare anthropometric indexes and hormone concentrations
by treatment group at 2 times during the study. The models with
anthropometric indexes as the dependent variables included the
following covariates: time, group  time, initial z score, and
initial z score  time. The models with leptin and ghrelin con-
centrations as dependent variables included the covariates time,
group  time, initial hormone concentration, initial hormone
concentration  time, weight, weight  time, and sex. The
models with insulin and glucose as dependent variables also
included energy intake 90 min before the blood sampling as a
covariate. Spearman correlations were used to assess relations
between hormones and between hormones and anthropometric
indexes. Partial correlations were used to assess relations be-
tween hormones and presampling meal components, with con-
trol for body weight. Analysis of covariance (PROC GLM) was
used to examine relations between hormone concentrations and
growth. To determine whether leptin or ghrelin concentrations
were more strongly predicted by current weight status or prior
growth, the independent variables were standardized, and the 
coefficients from the regression analyses using the standardized
variables were compared by t test.
RESULTS
Plasma hormone and glucose concentrations
There were no differences in initial plasma ghrelin, insulin, or
glucose concentrations by treatment group. However, plasma
leptin concentrations at baseline were significantly lower in the
ZnSuppl group than in the ZnFort group (Table 1). After baseline
values were controlled for sex, and body weight, there were no
group  time interactions in plasma concentrations of leptin,
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ghrelin, or glucose. In other words, treatment group did not affect
these outcomes at either time point. There was a significant group
 time effect on insulin concentrations (P 0.007). In particu-
lar, regression analyses of the change in log insulin showed a
significantly greater decrease in insulin concentrations from
baseline to 6 mo in the control group than in the zinc-fortification
group (P  0.01), but neither of these groups differed signifi-
cantly from the ZnSuppl group.
Considering all treatment groups combined, plasma leptin
concentrations decreased and ghrelin concentrations increased
from baseline to 3 mo with no further change from 3 to 6 mo
(Table 1). Insulin concentrations decreased from baseline to 6
mo. Glucose concentrations decreased from 3 to 6 mo. Girls had
higher concentrations of plasma leptin and ghrelin, and the in-
teraction between sex and time was significant for both leptin and
ghrelin (P  0.01) after BMI was controlled for. Plasma leptin
concentrations were significantly greater in girls at all time
points, and plasma ghrelin concentrations were greater in girls at
baseline only (Figure 2). Girls had significantly higher concen-
trations of plasma leptin per kg of body fat than did boys at 6 mo
(1.1 compared with 0.8 ng  mL1  kg1; P  0.0001). Leptin
concentrations were positively correlated with insulin concen-
trations (r  0.20–0.43, P  0.01) at all time points and with
glucose at baseline (r 0.20, P 0.05) and 3 mo (r 0.24, P
0.05). Ghrelin concentrations were not correlated with the other
hormones or glucose at any time point. Insulin and glucose con-
centrations were positively correlated at all time points (r 
0.29–0.46, P 0.01).
Anthropometric measures and body composition
No group-wise differences were found in anthropometric z
scores or body composition at baseline or 3 or 6 mo after the start
of the zinc intervention. Therefore, the anthropometric and body-
composition indexes of all children were combined for all treat-
ment groups, and the results are presented for the 3 time points in
Table 2. The mean weight-for-age z scores (WAZ) and LAZ
decreased at each follow-up time (P 0.0001). WLZ decreased
at 3 mo (P 0.0001), but did not change further from 3 to 6 mo.
The children gained an average of 1.3 kg over the 6 mo. The ma-
jority of the weight gain consisted of FFM (94 94%; median
74%), and percentage body fat (%FM) decreased over the 6 mo
(P 0.001). Body weight was positively associated with %FM
at baseline and 6 mo (P  0.001). After body weight was con-
trolled for, girls had a higher %FM than did boys at both time
points (P 0.05).
Dietary energy intake before blood sampling
The average energy intakes from the milk feeding 90 min
before the blood sampling were 50 31, 36 21l, and 43 22
kcal at baseline, 3 mo, and 6 mo respectively. At baseline only,
energy intakes were positively correlated with plasma concen-
trations of insulin (r 0.35, P 0.001) and glucose (r 0.25,
P0.05) after body weight was controlled for. Plasma leptin and
ghrelin concentrations were not related to the energy content of
the milk feeding before the blood sampling.
Relations between plasma hormone concentrations and
anthropometric measures and body composition
Cross-sectional correlations between both leptin and ghrelin
concentrations and anthropometric indexes at all 3 time points
are presented in Table 3. In general, leptin concentrations were
positively correlated with anthropometric indexes. There was a
positive correlation between leptin and FM at both baseline and
TABLE 1
Plasma leptin, ghrelin, insulin, and glucose concentrations by zinc-treatment group at baseline (0 mo) and 3 and 6 mo1
ZnSuppl ZnFort Control
P for
model 12
All groups
combined
P for
model 23
Leptin (ng/mL) — — — 0.99 — 0.0001
0 mo 2.9 0.9 [47] 3.4 1.1 [49] 3.4 1.2 [46] — 3.2 1.1a [142] —
3 mo 2.6 0.8 [40] 2.7 0.7 [39] 2.9 1.3 [44] — 2.7 1.0b [123] —
6 mo 2.6 0.8 [36] 2.8 0.9 [37] 2.7 0.8 [44] — 2.7 0.8b [117] —
Ghrelin (pg/mL)
0 mo 371 94 [40] 396 131 [20] 390 113 [45] 0.82 384 110a [105] 0.02
3 mo 403 111 [40] 418 138 [20] 415 146 [44] — 411 131b [104] —
6 mo 403 136 [36] 404 115 [19] 423 111 [44] — 412 121a,b [99] —
Insulin (U/mL)
0 mo 3.9 1.5 [47] 4.6 2.1 [49] 5.0 3.7 [46] 0.007 4.5 2.6a [142] 0.0005
3 mo 3.4 1.6 [40] 4.2 1.8 [38] 4.5 4.0 [44] — 4.1 2.8a,b [122] —
6 mo 3.4 1.3 [36] 4.2 1.6 [37] 3.4 1.6 [44] — 3.7 1.5b [117] —
Glucose (mg/dL)
0 mo 77.4 6.0 [39] 78.7 6.6 [20] 78.1 6.4 [44] 0.41 78.0 6.2a,b [103] 0.04
3 mo 77.1 5.9 [40] 80.3 9.3 [20] 80.4 9.0 [44] — 79.1 8.1a [104] —
6 mo 76.6 6.7 [36] 77.1 5.7 [19] 77.2 5.5 [44] — 76.9 5.9b [99] —
1 All values are x  SD; n in brackets. ZnFort, zinc-fortified group; ZnSuppl, zinc supplement group.
2 Model 1 is a mixed model with repeated measures (PROC MIXED) that examined the effect of treatment group over time. The P value is for the treatment
group time interaction. Leptin, ghrelin, and insulin were log transformed. The models with leptin and ghrelin as the dependent variables included the following
covariates: time, group time, initial hormone, initial hormone time, weight, weight time, and sex. The models with insulin and glucose as the dependent
variables included the following covariates: time, group time, initial insulin/glucose value, initial insulin/glucose time, weight, weight time, sex, and
presampling energy intake. ANOVA was used to examine initial (0 mo) differences among treatment groups. There was a significant difference in 0-mo leptin
values between the ZnSuppl and ZnFort groups (P 0.03).
3 Model 2 is a mixed model with repeated measures (PROC MIXED) that examined the effect of time. The P value is for the variable time. Means in a
column with different superscript letters are significantly different, P 0.05.
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6 mo. On the other hand, ghrelin was inversely correlated with
weight, WAZ, BMI, and arm circumference. Ghrelin was also
inversely correlated with FFM at 6 mo, but not with FM.
Multiple regression analyses were performed to examine the
relations of leptin and ghrelin concentrations with prior and sub-
sequent growth. Analyses were conducted with the 2 growth
intervals: baseline to 3 mo and 3 to 6 mo. The results were similar
during both growth intervals; therefore, for simplicity, we are
presenting just the models relating to the 6-mo growth interval
(baseline to 6 mo) for leptin (Table 4) and ghrelin (Table 5).
Leptin at baseline was positively related to WAZ at baseline
(model 1), but was not predictive of the subsequent change in
WAZ (model 2). However, change in WAZ (WAZ) from base-
line to 6 mo was positively predictive of leptin at 6 mo (model 3).
Current WAZ at 6 mo was also positively related to leptin at 6 mo
(model 4). When bothWAZ and current WAZ were included in
the same model, neither was significant (model 5). To determine
whether one of these variables was more strongly associated with
leptin at 6 mo, WAZ at 6 mo andWAZ were standardized, and
regression analyses were repeated with the standardized vari-
ables. There was no difference in the standardized  coefficients
for WAZ at 6 mo and WAZ (model 5: t  0.17, P  0.43),
which indicated that neither of these variables was more predic-
tive of leptin than the other. Ghrelin at baseline was not related to
WAZ at baseline (model 1) or with subsequentWAZ (model 2).
BothWAZ (model 3) and current WAZ (model 4) at 6 mo were
negatively predictive of ghrelin at 6 mo in separate models.
However, when both were included in the same model, only
WAZ was significant (model 5).
The relations of leptin and ghrelin concentrations with prior
and subsequent changes in WLZ were similar to the relations
previously described for changes in WAZ. That is, WLZ was
positively predictive of subsequent leptin concentrations and
negatively predictive of subsequent ghrelin concentrations.
There were no differences in the strength of the relations with
hormones between WAZ and WLZ when the standardized 
coefficients were compared. There was no relation between
changes in LAZ and leptin or ghrelin concentrations.
Despite the positive relation between leptin concentrations
and FM at baseline and 6 mo (Table 3), there were no associations
between leptin and prior or subsequent changes in FM or %FM
(data not shown). In contrast, FFM was a positive predictor of
Pl
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300
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FIGURE 2. Mean (SE) plasma leptin and ghrelin concentrations by sex
and month of study after control for BMI in boys and girls aged 6–8 mo. A
mixed model was used (PROC MIXED; SAS Institute Inc, Cary, NC) to
examine the relation between sex and time. There was a significant interac-
tion between sex and month of study for both leptin and ghrelin (P 0.01).
TABLE 2
Anthropometric indexes and body-composition variables measured at 3-mo intervals1
Baseline (n 142) 3 mo (n 126) 6 mo (n 118) P2
Anthropometric indexes
Weight (kg) 7.6 0.8a 8.3 0.9b 8.9 0.9c 0.0001
Length (cm) 65.2 1.8a 69.1 1.9b 71.9 1.9c 0.0001
WAZ 0.71 0.84a 1.19 0.88b 1.33 0.84c 0.0001
LAZ 1.19 0.51a 1.28 0.56b 1.44 0.52c 0.0001
WLZ 0.51 0.91a 0.12 1.02b 0.11 0.92b 0.0001
BMI (kg/m2) 17.8 1.5a 17.3 1.5b 17.3 1.4b 0.0001
MUAC (cm) 14.5 1.1a — 14.6 1.1a 0.19
MUAC z score 0.14 0.92a — 0.70 0.80b 0.0001
Body composition3
Fat-free mass (kg) 4.96 0.66a — 6.00 0.69b 0.0001
Fat mass (kg) 2.66 0.66a — 2.94 0.77b 0.0001
Fat mass (% of body weight) 34.8 7.0a — 32.6 6.9b 0.0002
1 All values are xSD. WAZ, weight-for-age z score; LAZ, length-for-age z score; WLZ, weight-for-length z score; MUAC, midupper arm circumference.
2 Variables were compared by time with the use of a mixed model with repeated measures (PROC MIXED; SAS Institute, Cary, NC); values in a row with
different superscript letters are significantly different, P 0.001.
3 n 127 at baseline and n 116 at 6 mo.
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leptin at 6 mo (P 0.05); however, this relation did not remain
significant when FFM at 6 mo (which was not significant) was
included in the model. In separate models with WAZ as the
dependent variable, both FFM and FM were positively
associated with WAZ (P  0.001). However, the standard-
ized  coefficient for FM (  0.32) was significantly
greater than that for FFM (  0.20; t  2.3, P  0.01). In
addition, the percentage of the 6-mo weight gain that was FM
was positively associated with WAZ. In contrast, the per-
centage of weight gain that was FFM was negatively associ-
ated with WAZ. In other words, infants with the greatest
weight gain or WAZ had a greater percentage of that weight
gain as FM. However, the percentage of weight gain that was FM
was not predictive of leptin at 6 mo, nor was the change in %FM
or %FFM. The only relation found between ghrelin concentra-
tion and body-composition measures was a negative association
between ghrelin at 6 mo and FFM at 6 mo (P  0.05). In a
regression model of the change in ghrelin over 6 mo, there was a
negative relation between the changes in ghrelin and FFM (P
0.01). There was a significant interaction between change in
FFM and change in WAZ (P  0.05), ie, only among children
with weight gain less than the median value ofWAZ was there
a negative relation between change in ghrelin and change in
FFM.
TABLE 3
Spearman correlation coefficients between hormones and anthropometric measures at the same time point1
Leptin Ghrelin
Baseline 3 mo 6 mo Baseline 3 mo 6 mo
r n r n r n r n r n r n
Maternal BMI2 0.173 (139) 0.203 (121) 0.01 (115) 0.10 (103) 0.07 (102) 0.02 (97)
Birth weight2 0.12 (134) 0.08 (119) 0.02 (113) 0.11 (101) 0.02 (100) 0.09 (95)
Weight 0.284 (142) 0.275 (123) 0.12 (117) 0.285 (105) 0.325 (104) 0.315 (99)
WAZ 0.466 (142) 0.396 (123) 0.305 (117) 0.16 (105) 0.233 (104) 0.255 (99)
Length 0.183 (142) 0.13 (123) 0.213 (117) 0.12 (105) 0.253 (104) 0.17 (99)
LAZ 0.01 (142) 0.05 (123) 0.03 (117) 0.08 (105) 0.09 (104) 0.05 (99)
WLZ 0.516 (142) 0.456 (123) 0.354 (117) 0.223 (105) 0.203 (104) 0.275 (99)
BMI 0.486 (142) 0.436 (123) 0.304 (117) 0.253 (105) 0.223 (104) 0.265 (99)
MUAC 0.506 (142) — 0.376 (117) 0.233 (105) — 0.253 (99)
MUAC z score 0.566 (142) — 0.466 (117) 0.11 (105) — 0.223 (99)
FFM 0.09 (127) — 0.07 (115) 0.17 (97) — 0.223 (97)
FM 0.426 (127) — 0.245 (115) 0.08 (97) — 0.12 (97)
Percentage FM 0.396 (127) — 0.213 (115) 0.01 (97) — 0.04 (97)
1 WAZ, weight for age z score; LAZ, length-for-age z score; WLZ, weight-for-length z score; MUAC, midupper arm circumference; FFM, fat-free mass;
FM, fat mass.
2 The x ( SD) maternal BMI (in kg/m2) was 25.4 3.7, and the reported birth weight was 3.1 0.4 kg.
3 P 0.05.
4 P 0.001.
5 P 0.01.
6 P 0.0001.
TABLE 4
Multiple regression models that examined the relation between plasma leptin concentrations and weight-for-age z score (WAZ) and change in WAZ
(WAZ) during a 6-mo period (from baseline to 6 mo)
Model1 Dependent variable Independent variable
 Coefficent
(P)
Standardized  Coefficient
 SE2
13 log Leptin, baseline WAZ, baseline 0.17 (0.0001) —
24 WAZ, from baseline to 6 mo log Leptin, baseline 0.08 (0.67) —
35 log Leptin, 6 mo WAZ, from baseline to 6 mo 0.14 (0.003) 0.075 0.025
46 log Leptin, 6 mo WAZ, 6 mo 0.10 (0.003) 0.082 0.027
57 log Leptin, 6 mo WAZ, from baseline to 6 mo 0.09 (0.07) 0.051 0.028
WAZ, 6 mo 0.07 (0.07) 0.056 0.030
1 Data were analyzed by using ANCOVA (PROC GLM; SAS Institute Inc, Cary, NC).
2 The primary independent variables for models 3–5 were standardized, and coefficients for standardized variables were determined by using ANCOVA
(PROC GLM); t tests conducted to compare standardized  coefficients from models 3 and 4, and with standardized  coefficients from model 5, determined
that there was no difference in the strength of the relation between WAZ at 6 mo and WAZ from baseline to 6 mo and leptin at 6 mo (t 0.17, P 0.43).
3 Model 1 (n 142) controlled for sex (NS).
4 Model 2 (n 118) controlled for WAZ at baseline (0.21, P 0.004) and sex (NS).
5 Model 3 (n 117) controlled for log leptin at baseline ( 0.37, P 0.0001) and sex (FM, P 0.0001).
6 Model 4 (n 117) controlled for log leptin at baseline ( 0.24, P 0.005) and sex (FM, P 0.0001).
7 Model 5 (n 117) controlled for log leptin at baseline ( 0.29, P 0.001) and sex (FM, P 0.0001).
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DISCUSSION
Contrary to our hypotheses, we did not find differences in
plasma leptin, ghrelin, or glucose concentrations between infants
who received zinc supplements or zinc-fortified food for 6 mo
and infants who did not receive additional zinc. Although chil-
dren in the control group had a significantly greater decrease in
plasma insulin concentrations during the 6-mo study than did
children who received the zinc-fortified porridge, the change in
insulin concentrations among children receiving zinc in a liquid
supplement did not differ from that of the control group. Thus, it
is possible that the insulin results observed in the ZnFort group
were spurious because we would have expected to see the same
effect with the liquid zinc supplement if these results were due to
zinc. In a previous analysis we found that children in the ZnSuppl
group had a significant increase in plasma zinc concentrations,
but children in the ZnFort group did not (15). Thus, it seems
unlikely that the insulin results could have been due to differ-
ences in zinc absorption.
Supplemental zinc also had no effect on the infants’ growth.
Possible explanations for the lack of zinc-induced differences in
child growth and appetite-related hormone concentrations could
be poor compliance with the intervention, inadequate dose of
zinc, or absence of zinc deficiency in the study population. In
fact, compliance with taking the liquid zinc supplement was very
good; children in all groups consumed the supplement on 98% of
the days, and the average porridge consumption was 23 g/d.
Thus, poor compliance is an unlikely explanation for the ob-
served results. The zinc dose of 3 mg/d used in this study was less
than the amounts administered in many previous supplementa-
tion trials (22–26). Nevertheless, this dose is consistent with the
recently revised Recommended Dietary Allowance of 3 mg/d
and less than the Upper Tolerable Limit of 5 mg for young
children between the ages of 7–12 mo (27). Thus, the dose of zinc
provided should have been adequate to satisfy the theoretical
requirement.
Although there is no valid indicator to identify mild-to-
moderate zinc deficiency in individuals, the risk of zinc defi-
ciency in a population can be assessed on the basis of the prev-
alence of low plasma zinc concentrations or inadequate dietary
zinc and the percentage of the population with a low height-for-
age z score (28). The children in the present study were selected
to be at high risk of zinc deficiency based on their initial LAZ
0.5. However, the final mean LAZ was 1.3, so the children
did not become as stunted as did those in earlier studies, and they
may not have been sufficiently stunted to respond to zinc. Current
guidelines suggest that a population is considered to have a high
risk of zinc deficiency when 20% of the plasma zinc concen-
trations are less than reference cutoffs. However, only 17% of
infants in our study had low plasma zinc concentrations (65
g/dL) at baseline, which suggests that this population may not
have been zinc deficient.
Despite a lack of effect of zinc on the hormone concentrations
or growth of the children, our study design allowed us to examine
both cross-sectional and longitudinal relations between the hor-
mones and anthropometric indexes and body composition. Our
study was unique in that we measured plasma leptin and ghrelin
concentrations multiple times and examined periods of growth
both before and after the hormones were measured while con-
trolling for other factors related to these hormones, such as pre-
vious hormone concentrations and child sex. We found that
plasma concentrations of leptin and ghrelin were not predictive
of subsequent growth, but were related to prior growth as well as
current weight status. The strength of the associations between
current weight status and prior weight change were similar, so we
were unable to determine whether prior growth or current status
is a more important determinant of these hormone concentra-
tions. Nevertheless, these findings suggest a role for leptin and
ghrelin that may be compensatory for, rather than causative of,
weight changes during later infancy.
A compensatory role for leptin and ghrelin has been noted in
other studies. Leptin circulates in proportion to FM and decreases
with weight loss (29). On the other hand, plasma ghrelin con-
centration are increased during weight loss and in patients with
anorexia nervosa and are higher in obese than in lean individuals
(30). In Gambian infants, leptin concentrations were positively
related to prior changes in BMI z scores, but not with subsequent
growth (8). Another study in Italian infants reported a negative
association between weight gain since birth and subsequent
TABLE 5
Multiple regression models that examined the relation between plasma ghrelin concentrations and weight-for-age z score (WAZ) and change in WAZ
(WAZ) during a 6-mo period (from baseline to 6 mo)
Model1 Dependent variable Independent variable
 Coefficient
(P)
Standardized 
coefficient SE2
13 log Ghrelin, baseline WAZ, baseline 0.04 (0.18) —
24 WAZ, from baseline to 6 mo log Ghrelin, baseline 0.09 (0.70) —
35 log Ghrelin, 6 mo WAZ, from baseline to 6 mo 0.14 (0.002) 0.081 0.025
46 log Ghrelin, 6 mo WAZ, 6 mo 0.07 (0.02) 0.060 0.026
57 log Ghrelin, 6 mo WAZ, from baseline to 6 mo 0.12 (0.02) 0.068 0.027
WAZ, 6 mo 0.04 (0.24) 0.033 0.028
1 Data were analyzed by using ANCOVA (PROC GLM; SAS Institute Inc, Cary, NC).
2 The primary independent variables for models 3–5 were standardized, and  coefficients for standardized variables were determined by using linear
regression; t tests conducted to compare standardized  coefficients from models 3 and 4, and with standardized  coefficients from model 5, determined that
there was no difference in the strength of the relation between WAZ at 6 mo and WAZ from baseline to 6 mo and ghrelin at 6 mo (t 1.25, P 0.11).
3 Model 1 (n 105) controlled for sex (FM, P 0.0006).
4 Model 2 (n 99) controlled for at baseline WAZ (0.22, P 0.003) and sex (NS).
5 Model 3 (n 99) controlled for log ghrelin at baseline ( 0.50, P 0.0001) and sex (NS).
6 Model 4 (n 99) controlled for log ghrelin at baseline ( 0.47, P 0.0001) and sex (NS).
7 Model 5 (n 99) controlled for log ghrelin at baseline ( 0.48, P 0.0001) and sex (NS).
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ghrelin concentrations during the first year of life (31). Our
findings of a positive relation between current body weight or
BMI and leptin and of an inverse relation between weight and
ghrelin are also consistent with other reports on leptin (8–11) and
ghrelin (10, 12–14) concentrations during infancy.
In contrast with our findings and those of others of a compen-
satory role for leptin and ghrelin during infant growth, some
studies have found an association between these hormones mea-
sures at birth and subsequent growth during infancy. Ong et al (9)
reported that cord blood leptin was a negative predictor of weight
gain from birth to 4 mo of age (P 0.005). James et al (32) found
that low ghrelin concentrations in cord blood at birth were asso-
ciated with slow weight gain over the first 3 mo of life, although
they found no relation between leptin and subsequent growth.
We found no associations between leptin or ghrelin and subse-
quent weight change during later infancy; however, it is possible
that hormone concentrations in the newborn have a role in growth
early in infancy, but not later.
Our finding that leptin concentrations were significantly
higher in girls than in boys after BMI was controlled for agrees
with the findings of other studies (8, 33). The female children in
our study had a higher %FM; however, leptin concentrations
were higher at 6 mo even after %FM was controlled for. The
reason for higher leptin concentrations in females is unclear;
however, it has been reported that leptin expression in vitro and
in vivo is suppressed by androgens and promoted by estrogens
(34). In contrast with leptin, most studies have found no sex
differences in ghrelin concentrations during infancy (10, 12, 14,
31, 35). We found higher ghrelin concentrations in girls at base-
line, but not at the later time points.
The disparity between the relations between hormones and
changes in WAZ compared with FFM or FM is puzzling.
Changes in WAZ was more strongly related to changes in FM
than with changes in FFM, although both were related to changes
in WAZ. The changes in WAZ and changes in FFM predicted
final plasma leptin concentrations at 6 mo, whereas changes in
FM did not. Because 94% of the weight gained by these children
over the 6 mo of the study was due to increased FFM, it appears
likely that changes in WAZ would be more closely related to
changes in FFM. However, children who gained more weight had
a greater percentage of that weight gain as FM. There was great
variability in the percentage of weight gain that was FM; there-
fore, the lack of measurement precision may explain the lack of
an association with subsequent leptin concentrations.
In conclusion, supplemental zinc did not influence plasma
leptin or ghrelin concentrations in this population of young chil-
dren. Plasma leptin and ghrelin concentrations were associated
with both current weight status and prior growth but not with
subsequent growth during a 3- or 6-mo period. However, some
evidence suggests that early metabolic programming may affect
the future risk of obesity (36). Despite our findings of no association
with short-term growth, it is possible that these hormones may have
more long-term effects on weight and body composition in later
childhood. Further research is needed to determine whether leptin
and ghrelin during periods of undernutrition in infancy may affect
long-term body weight and body composition.
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